Asset Details
Do you wish to reserve the book?
Sociodemographic factors and biologic therapy exposure impacting health-related quality of life in psoriatic arthritis - findings from a nationwide registry Reuma.pt
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Sociodemographic factors and biologic therapy exposure impacting health-related quality of life in psoriatic arthritis - findings from a nationwide registry Reuma.pt
Do you wish to request the book?
Sociodemographic factors and biologic therapy exposure impacting health-related quality of life in psoriatic arthritis - findings from a nationwide registry Reuma.pt
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Sociodemographic factors and biologic therapy exposure impacting health-related quality of life in psoriatic arthritis - findings from a nationwide registry Reuma.pt
2025
Overview
Psoriatic arthritis (PsA) is a very heterogeneous disease with significant impact on health-related quality-of-life (HRQoL). Our objective was to assess and identify predictors of HRQoL in a 3-year follow-up period among PsA patients. Patients with PsA included in the Rheumatic Diseases Portuguese Register (Reuma.pt), with HRQoL data measured by the EuroQoL five Dimensions (EQ-5D) with at least two evaluations throughout a 3-year period, were analysed. Statistics included
t-
tests, logit and linear mixed models and univariable and multivariable linear regression. PsA patients’ (
n
= 342) mean age 51.0 (12.2) years, 48.5% being female, mean disease duration 11.8 (9.3) years with a follow-up period of 3-years had a mean EQ-5D of 0.53 (0.28), 0.59 (0.29), and 0.58 (0.28) at baseline, 1-year and 3-year evaluations, respectively. During the follow-up period, EQ-5D score and EQ VAS, significantly improved at both time-point assessments, compared to baseline. Poorer HRQoL was significantly associated with older age (β=-0.004; p-value = 0.008), female sex (β=-0.092; p-value = 0.01), non-employment (β=-0.112; p-value = 0.018), higher disease activity (β=-0.005; p-value < 0.001), prior exposure of three or more biologics at baseline and switching of biologic therapy during the study follow-up [(β=-0.182; p-value = 0.04); (β=-0.150; p-value = 0.002), respectively]. Our study provides important insights into the long-term predictors of HRQoL in PsA patients, highlighting the influence of sociodemographic factors, disease activity and therapeutic approach (prior use and switch/cycle of biologic therapies) on HRQoL.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 692/4023
/ Adult
/ Age
/ Arthritis, Psoriatic - drug therapy
/ Arthritis, Psoriatic - epidemiology
/ Arthritis, Psoriatic - psychology
/ Arthritis, Psoriatic - therapy
/ Female
/ Females
/ Humanities and Social Sciences
/ Humans
/ Male
/ Nonsteroidal anti-inflammatory drugs
/ Patient reported outcome measures determinants of health
/ Patients
/ Science
We currently cannot retrieve any items related to this title. Kindly check back at a later time.